Anti B cell therapy (rituximab) in the treatment of autoimmune diseases

被引：62

作者：

Kazkaz, H ^{[1
]}

Isenberg, D ^{[1
]}

机构：

[1] Middlesex Hosp, Ctr Rheumatol, London W1T 4NJ, England

来源：

CURRENT OPINION IN PHARMACOLOGY | 2004年 / 4卷 / 04期

关键词：

D O I：

10.1016/j.coph.2004.03.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

B cells play an important role in the pathogenesis of many autoimmune diseases. Selective targeting of these cells has been recently achieved using a chimeric monoclonal antibody against the pan B cell surface marker CD20 (rituximab). This antibody was originally developed for the treatment of non-Hodgkin's lymphoma. It was found to be effective, well tolerated and had a very good safety profile. Recent studies have demonstrated the efficacy of rituximab in several refractory autoimmune disorders including rheumatoid arthritis, systemic lupus erythematosus, immune thrombocytopenic purpura, chronic cold agglutinin disease, IgM-mediated neuropathies and mixed cryoglobulinemia.

引用

页码：398 / 402

页数：5

共 32 条

[1]

AHERNS N, 2001, BRIT J HAEMATOL, V114, P244

[2]

Anolik JH, 2002, ARTHRITIS RHEUM-US, V46, pS289

[3] Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment [J].

Auner, HW ;

Wölfler, A ;

Beham-Schmid, C ;

Strunk, D ;

Linkesch, W ;

Sill, H .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (03) :727-728

[4] Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients [J].

Berentsen, S ;

Ulvestad, E ;

Gjertsen, BT ;

Hjorth-Hansen, H ;

Langholm, R ;

Knutsen, H ;

Ghanima, W ;

Shammas, FV ;

Tjonnfjord, GE .

BLOOD, 2004, 103 (08) :2925-2928

[5] Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease [J].

Berentsen, S ;

Tjonnfjord, GE ;

Brudevold, R ;

Gjertsen, BT ;

Langholm, R ;

Lokkevik, E ;

Sorbo, JH ;

Ulvestad, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :79-83

[6] TRANSFECTION OF THE CD20 CELL-SURFACE MOLECULE INTO ECTOPIC CELL-TYPES GENERATES A CA2+ CONDUCTANCE FOUND CONSTITUTIVELY IN B-LYMPHOCYTES [J].

BUBIEN, JK ;

ZHOU, LJ ;

BELL, PD ;

FRIZZELL, RA ;

TEDDER, TF .

JOURNAL OF CELL BIOLOGY, 1993, 121 (05) :1121-1132

[7]

Cohen Y, 2003, HAEMATOLOGICA, V88, P811

[8] Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis - Evidence for a pathogenetic role of B cells [J].

De Vita, S ;

Zaja, F ;

Sacco, S ;

De Candia, A ;

Fanin, R ;

Ferraccioli, G .

ARTHRITIS AND RHEUMATISM, 2002, 46 (08) :2029-2033

[9] Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody) [J].

Dupuy, A ;

Viguier, M ;

Bédane, C ;

Cordoliani, F ;

Blaise, S ;

Aucouturier, F ;

Bonnetblanc, JM ;

Morel, P ;

Dubertret, L ;

Bachelez, H .

ARCHIVES OF DERMATOLOGY, 2004, 140 (01) :91-96

[10] Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes [J].

Edwards, JCW ;

Cambridge, G .

RHEUMATOLOGY, 2001, 40 (02) :205-211

← 1 2 3 4 →